Manuel Martinez-Selles, MD, of the cardiology department at Hospital General Universitario Gregorio Maranon in Madrid, Spain, and colleagues noted that randomized clinical trials fail to accurately reflect the proportion of women who have HF.
Older age or HF with preserved EF are more prevalent in women, and also may be exclusion criteria in trials.
Previous studies, some of which were based on small numbers of patients, have had conflicting results.
Martinez-Selles and colleagues aggregated data from 31 randomized and observational studies from the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) individual patient meta-analysis for their assessment.
"Perhaps surprisingly, this was particularly evident in patients with reduced EF, where the evidence for these therapies is strongest," Martinez-Selles and colleagues wrote.